Standverwaltung
Option auswählen

HaploPharma Inc.

3-2-9, Nihonbashi, Chuo-ku (Sansho Building. 4F), 103-0027 Tokyo
Japan

Dieser Aussteller ist Mitaussteller von
Japan Agency for Medical Research and Development

Hallenplan

MEDICA 2019 Hallenplan (Halle 15): Stand H16

Geländeplan

MEDICA 2019 Geländeplan: Halle 15

Ansprechpartner

Yasunori Iwamoto

Telefon
+81 3 32745070

E-Mail
yasunori.iwamoto@haplopharma.com

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.02  Immunochemie / Immunologie
  • 03.02.02  Diagnose-Schnelltests

Diagnose-Schnelltests

Unsere Produkte

Produktkategorie: Diagnose-Schnelltests

ExpressGenotyping™

The understanding of drug-related toxicity in early stages of development is one of the key issues for better drug development. Despite the usefulness of pharmaco-genomics in the drug development process, it remains largely an expensive and cumbersome process for drug-induced toxicity studies. This is partly due to the large number of clinical samples required and complicated statistical methodologies employed for the pharmacogenomic studies of drug-induced adverse effects.

As shown in the past, integration of data from genotype, gene expression and drug sensitivity is able to identify genetic variants critical in drug-related toxicity. Although informative, such methods use a large number of cell lines and clinical samples due to the limits of conventional gene expression and genotyping analyses.

To overcome these shortcomings ExpressGenotyping™ technology was developed jointly with the group of Prof. Aburatani and Prof. Ishikawa (Research Center for Advanced Science and Technology, University of Tokyo).

ExpressGenotyping™ can efficiently and genome-widely explore and pick up candidate Biomarker SNPs which may affect drug kinetics, efficacy, and toxicity in the human body.

Mehr Weniger

Über uns

Firmenporträt

Our company is focusing on the development of new health care services based on genetic information and on advanced pharmacogenomics. We are developing technologies to discover genetic biomarkers for the prediction of individual drug response.

Our novel technology ExpressGenotyping™ doesn't require complex study designs and computation. Nevertheless you will be able to obtain with this technology valuable results with a relatively small number of samples and within only a few months. HaploPharma offers ExpressGenotyping™ analysis on samples of customers' interest, creating information which should immensely promote our customers' R&D.

Mehr Weniger